Advertisement

Neuroimmunological Molecules and Translational Medicine

  • Andrew R. Pachner
Chapter

Abstract

Basic neuroscience is a rapidly moving field, and the nervous system is a vast frontier only a small fraction of which has been explored. The potential for discovery of new molecules and concepts in basic neuroscience to be directly applied to the treatment of human neurological disease is high. However, this potential is not fulfilled as often as possible for a multitude of reasons, some of which were dramatized in the recent popular movie “Extraordinary Measures” in which a new enzyme replacement therapy for Pompe’s disease, a glycogen storage disease with dramatic CNS complications, went through a number of hurdles from bench to bedside.

Keywords

Experimental Autoimmune Encephalomyelitis Progressive Multifocal Leukoencephalopathy Enzyme Replacement Therapy Glycogen Storage Disease Progressive Multifocal Leukoencephalopathy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. Neurology. 1999;53(3):457–65.Google Scholar
  2. 2.
    Coles AJ, Compston DA, Selmaj KW, et al. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med. 2008;359(17):1786–801.PubMedCrossRefGoogle Scholar
  3. 3.
    O’Connor KC, Appel H, Bregoli L, et al. Antibodies from inflamed central nervous system tissue recognize myelin oligodendrocyte glycoprotein. J Immunol. 2005;175(3):1974–82.PubMedGoogle Scholar
  4. 4.
    Owens GP, Bennett JL, Lassmann H, et al. Antibodies produced by clonally expanded plasma cells in multiple sclerosis cerebrospinal fluid. Ann Neurol. 2009;65(6):639–49.PubMedCrossRefGoogle Scholar
  5. 5.
    Diener HC, Lees KR, Lyden P, et al. NXY-059 for the treatment of acute stroke: pooled analysis of the SAINT I and II Trials. Stroke. 2008;39(6):1751–8.PubMedCrossRefGoogle Scholar
  6. 6.
    Fisher M, Feuerstein G, Howells DW, et al. Update of the stroke therapy academic industry roundtable preclinical recommendations. Stroke. 2009;40(6):2244–50.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  • Andrew R. Pachner
    • 1
  1. 1.Department of Neurology and Neuroscience New Jersey Medical SchoolUniversity of Medicine and Dentistry of New JerseyNewarkUSA

Personalised recommendations